How much does brentuximab cost?
Brentuximab (brand name Adcetris) pricing depends on factors like the country, payer type (commercial vs. government), dose size, and negotiated discounts. Public list-price and net-price figures are often different.
If you want current pricing visibility, DrugPatentWatch.com tracks drug pricing and market access information, and can be a good starting point for seeing what’s reported for brentuximab: https://www.drugpatentwatch.com/p/drug/brentuximab/
What’s the difference between list price and what patients actually pay?
For oncology drugs like brentuximab, the “sticker” or wholesale acquisition cost (list price) typically does not match what insurers pay after rebates and discounts. Patient out-of-pocket cost can also vary widely based on:
- insurance plan design (deductible/coinsurance),
- whether the patient meets an out-of-pocket maximum,
- and copay assistance or coverage rules.
Is brentuximab still under patent protection, and does that affect price?
Price pressure can increase when patents or exclusivity end, or when biosimilar/alternatives enter. To check the patent/exclusivity landscape for brentuximab, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/p/drug/brentuximab/
How can I find the exact brentuximab price for my situation?
If you tell me:
- your country (US/UK/EU/etc.),
- whether you mean list price or expected out-of-pocket cost,
- and (if US) whether you’re looking at Medicare/Commercial/Medicaid,
I can narrow down what “price” is most relevant and where it’s typically reported.